Related Experiment Video

Updated: Apr 19, 2026

Dynamic Clamp Methods to Investigate Impaired Neuronal Excitability Associated with Autism
08:44

Dynamic Clamp Methods to Investigate Impaired Neuronal Excitability Associated with Autism

Published on: October 17, 2025

864

Tuberous sclerosis complex: the past and the future

Liesbeth De Waele1, Lieven Lagae, Djalila Mekahli

  • 1Department of Pediatric Neurology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium, liesbeth.dewaele@uzleuven.be.

Pediatric Nephrology (Berlin, Germany)
|December 24, 2014
PubMed

Insights

Tuberous Sclerosis Complex (TSC) patients face significant risks from renal lesions. This review covers updated diagnostic and management guidelines, emphasizing multidisciplinary care and novel mTOR inhibitor therapies.

Area of Science:

  • Nephrology
  • Genetics
  • Oncology

Background:

  • Renal lesions are a major cause of morbidity and mortality in Tuberous Sclerosis Complex (TSC).
  • Understanding TSC pathophysiology has revealed new therapeutic targets.
  • Mammalian target of rapamycin (mTOR) inhibitors show promise for TSC-related conditions.

Purpose of the Study:

  • To review updated recommendations for TSC diagnosis, surveillance, and management.
  • To highlight the importance of a multidisciplinary approach for this multi-systemic disease.
  • To discuss emerging therapeutic strategies, including mTOR inhibitors.

Main Methods:

  • Literature review of recent advances in TSC research.
  • Analysis of updated clinical guidelines and recommendations.
  • Synthesis of data from clinical trials on mTOR inhibitors for TSC.

Main Results:

  • Updated diagnostic criteria and surveillance protocols for TSC are now available.
  • mTOR inhibitors have demonstrated efficacy in treating various TSC-related tumors and lesions.
  • There is a recognized need for more natural history data and placebo-controlled trials in TSC.

Conclusions:

  • Novel recommendations provide a framework for improved TSC patient care.
  • Multidisciplinary follow-up is crucial for managing the multi-systemic nature of TSC.
  • Targeted therapies like mTOR inhibitors offer new hope for TSC management.

More Related Videos

Label-Free Non-Linear Optics for the Study of Tubulin-Dependent Defects in Central Myelin08:07

Label-Free Non-Linear Optics for the Study of Tubulin-Dependent Defects in Central Myelin

Published on: March 24, 2023

2.4K
Purification of Tubulin with Controlled Posttranslational Modifications and Isotypes from Limited Sources by Polymerization-Depolymerization Cycles07:54

Purification of Tubulin with Controlled Posttranslational Modifications and Isotypes from Limited Sources by Polymerization-Depolymerization Cycles

Published on: November 5, 2020

5.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Microtubules in Signaling01:22

Microtubules in Signaling

The primary cilium, made up of microtubules, acts as antennae on the cell surfaces for relaying external stimuli into the cells. These fine hair-like structures are present, generally one per cell. These are non-motile cilia in a 9+0 microtubules arrangement, where the central pair of microtubules are absent. The primary cilia arise from the basal body embedded in the cell membrane. Intraflagellar transport (IFT) carries requisite proteins from the cytoplasm to the cilium because the primary...
2.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
Assembly of Complex Microtubule Structures01:32

Assembly of Complex Microtubule Structures

Complex microtubule structures are present in resting cells and in dividing cells. In resting cells, they are responsible for maintaining the cellular architecture, tracks for intracellular transport, positioning of organelles, assembly of cilia and flagella. They mediate the bipolar spindle assembly for chromosomal segregation and positioning of the cell division plate in dividing cells. The formation of microtubule complex structures depends on the cell type, cell stage, and cell function.
2.9K
Microtubule Associated Proteins (MAPs)01:42

Microtubule Associated Proteins (MAPs)

Microtubule function and architecture are regulated by an array of specialized proteins called microtubule-associated proteins or MAPs. These proteins are widespread across different organisms and have conserved protein motifs, like the multi-TOG domain for tubulin binding found in the CLASP family of MAPs. Some MAPs are lineage-specific based on their conserved domains. Their functions depend upon the cytoskeletal architecture and cell type they are located within. In-plant cells, a specific...
6.4K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
11.1K